COVID-19 is an emerging, rapidly evolving situation.
As part of the NIH Intramural Program, CCR has shifted all non-mission-critical laboratory operations to a maintenance phase in order to promote physical distancing and diminished transmission risk of COVID-19. Effective Monday, March 23, 2020, only mission-critical functions within NIH research laboratories will be supported.
Every year, the Center for Cancer Research (CCR) makes remarkable contributions to the understanding, detection, treatment and prevention of cancer.
Tumor cells rely on genes to escape immune control. Understanding these genes is guiding immunotherapy’s promise for more patients.
New advances suggest opportunities to treat a broadening range of cancers with cell-based immunotherapies.
Keeping blood vessel-supporting cells in working order could reduce the risk of metastasis.
Activating the cellular stress response puts the brakes on overactive signaling by one of cancer’s most notorious growth promoters.
Temporary breaks keep DNA organized but put chromosomes at risk for cancer-promoting rearrangements.
Overlapping molecular profiles suggest a unified approach may improve diagnosis and treatment of two types of liver cancer.
A screen for hundreds of epigenetic regulators has turned up a novel approach for treating a pediatric cancer.
Visualizing a DNA-cutting complex in extraordinary detail reveals how it binds to target DNA and changes its shape.
Four years after CCR investigators began testing avelumab, the drug became the first approved for treatment of a rare disease.
Inappropriate gene activity disrupts chromosome segregation and generates a chromosomal abnormality, known as uniparental disomy, present in many cancer cells.
Combining immunotherapies could make it harder for cancer cells to become treatment-resistant.
Loss of a genome-organization factor gives a subset of cancer cells the ability to self-renew.
New faculty join CCR each year to contribute to our work of making breakthrough scientific discoveries to find cures and treatments for cancer.
We are proud of our CCR awardees who represent a spectacular array of accomplishments.
Each year, CCR licenses new technologies, publishes articles in peer-reviewed journals, opens new clinical trials and brings in thousands of patients and trainees.